secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2026-08-04T20:16:35+00:00
Accession:  0001193125-26-332858
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q2 revenue up 16% to $308M; raises FY2026 guidance to $1.24-1.30B
------------------------------------------------------------------------

- DAYBUE net sales $125M (+30% YoY); NUPLAZID net sales $183M (+10% adj. YoY).
- Full-year 2026 total revenue guidance raised to $1.24-1.30B; DAYBUE guidance raised to $480-510M.
- Phase 2 remlifanserin topline results for Alzheimer's disease psychosis expected Sept-Oct 2026.
- CHMP positive opinion for DAYBUE in EU for Rett syndrome; FDA Fast Track for remlifanserin.
- CEO reaffirms long-term ambition of ~$1.7B annual net sales by 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/0001193125-26-332858-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312526332858/acad-20260804.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-332858

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer